Book contents
- Frontmatter
- Contents
- List of contributors
- Foreword – Alan B. Scott
- Preface
- 1 The pretherapeutic history of botulinum toxin
- 2 Botulinum toxin: history of clinical development
- 3 Pharmacology of botulinum toxin drugs
- 4 Immunological properties of botulinum toxins
- 5 Treatment of cervical dystonia
- 6 Treatment of hemifacial spasm
- 7 Treatment of blepharospasm
- 8 Treatment of oromandibular dystonia
- 9 Treatment of focal hand dystonia
- 10 Botulinum toxin applications in ophthalmology
- 11 Botulinum toxin therapy of laryngeal muscle hyperactivity syndromes
- 12 The use of botulinum toxin in otorhinolaryngology
- 13 Spasticity
- 14 The use of botulinum toxin in spastic infantile cerebral palsy
- 15 Hyperhidrosis
- 16 Cosmetic uses of botulinum toxins
- 17 Botulinum toxin in the gastrointestinal tract
- 18 Botulinum toxin in urological disorders
- 19 Use of botulinum toxin in musculoskeletal pain and arthritis
- 20 The use of botulinum toxin in the management of headache disorders
- 21 Treatment of plantar fasciitis with botulinum toxin
- 22 Treatment of stiff-person syndrome with botulinum toxin
- 23 Botulinum toxin in tic disorders and essential hand and head tremor
- 24 Developing the next generation of botulinum toxin drugs
- Index
- References
6 - Treatment of hemifacial spasm
Published online by Cambridge University Press: 28 July 2009
- Frontmatter
- Contents
- List of contributors
- Foreword – Alan B. Scott
- Preface
- 1 The pretherapeutic history of botulinum toxin
- 2 Botulinum toxin: history of clinical development
- 3 Pharmacology of botulinum toxin drugs
- 4 Immunological properties of botulinum toxins
- 5 Treatment of cervical dystonia
- 6 Treatment of hemifacial spasm
- 7 Treatment of blepharospasm
- 8 Treatment of oromandibular dystonia
- 9 Treatment of focal hand dystonia
- 10 Botulinum toxin applications in ophthalmology
- 11 Botulinum toxin therapy of laryngeal muscle hyperactivity syndromes
- 12 The use of botulinum toxin in otorhinolaryngology
- 13 Spasticity
- 14 The use of botulinum toxin in spastic infantile cerebral palsy
- 15 Hyperhidrosis
- 16 Cosmetic uses of botulinum toxins
- 17 Botulinum toxin in the gastrointestinal tract
- 18 Botulinum toxin in urological disorders
- 19 Use of botulinum toxin in musculoskeletal pain and arthritis
- 20 The use of botulinum toxin in the management of headache disorders
- 21 Treatment of plantar fasciitis with botulinum toxin
- 22 Treatment of stiff-person syndrome with botulinum toxin
- 23 Botulinum toxin in tic disorders and essential hand and head tremor
- 24 Developing the next generation of botulinum toxin drugs
- Index
- References
Summary
Hemifacial spasm (HFS) is characterized as involuntary irregular clonic or tonic movements of the facial muscles innervated by the seventh cranial nerve on one side of the face and is most often a result of vascular compression of the facial nerve at the root exit zone (Wang & Jankovic,1998). Facial muscle twitches usually begin in the periocular region and can progress to involve the cheek and perioral muscles. Hemifacial spasm is usually unilateral; however, uncommonly, it can spread and affect the other side of the face. Atypical cases have been reported to initiate in the orbicularis oris and buccinator muscles and gradually spread upward to involve the orbicularis oculi (Ryu et al., 1998). Muscles involved in HFS include the orbicularis oculi, frontalis (rarely), corrugator, nasalis, zygomaticus, risorius, orbicularis oris, and sometimes the platysma. (See Figure 6.1).
Hemifacial spasm appears to be more prevalent in females; commonly begins in the fifth decade and tends to have a fluctuating course. In contrast to essential blepharospasm, symptoms often continue during sleep and can provoke insomnia. Emotion and stress tend to exacerbate facial twitching. Although benign, HFS can be disabling due to social embarrassment and from excessive closure of one eye interfering with vision. Symptoms can progress over time and facial weakness can develop. Hypertension is thought to be a risk factor for the development of HFS (Oliveira et al., 1999; Defazio et al., 2000, 2003).
- Type
- Chapter
- Information
- Manual of Botulinum Toxin Therapy , pp. 43 - 48Publisher: Cambridge University PressPrint publication year: 2009
References
- 1
- Cited by